Search

Lein Applied Diagnostics, a British company that develops blood glucose measuring for people with diabetes, has announced it has received further investment from its shareholder Seven Spires Investments. The company is seeking more investment to put a non-invasive blood glucose meter into clinical trials.

A new report from MIT suggests that universities should avoid concentrating too much on technology transfer.

Forget stem cells, pharmacogenomics and the next big cure - Michael Kenward gazes into his prophecy book to see what the physical sciences have in store for us this year. Or maybe not.

Sworn enemies within the technology and pharmaceutical industries are joining forces in a lobbying drive to persuade European Union lawmakers to change a draft law they say will stifle innovation in Europe by criminalising patent infringements, along with all forms of intellectual property infringements.

On inventive Californians, technology transfer, how to approach the business press, and other insights into R&D management.

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

A new Swedish company backed by government and business angels aims to create an entire funding ecosystem for young companies until they become ready for venture capital.

Microsoft is to open more research centres in Europe, in a move to step up its research collaboration and boost students' interest in the technology field.

On the glut of patenting, BASF's rising research budget, football fever in the Commons, and other insights into R&D management

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.

Better, brighter, faster – that's where photonic lasers are trying to take us. A lay guide to the technology.

With licensing and collaboration now the lifeblood of the drug industry, the annual BIO-Europe get-together was focused on partnering. Nuala Moran was there.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

A new proposal from the European Investment Fund seeks to accelerate the success of European technology transfer projects. A noble idea, says Mary Lisbeth D'Amico in her fortnightly column, but no one has yet stepped up to foot the bill.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?